• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only


      October: Episode 4     Watch time: 20 min

      BAD 2020 virtual congress highlights

      The fourth episode focuses on the latest updates and hot topics relating to SKYRIZI (risankizumab) and biologic treatment for moderate to severe psoriasis – presented at the 100th British Association of Dermatologists annual meeting – held virtually this year. 

      Podcast Series Host

      Dr Laura Savage

      University of Leeds and Leeds

      Teaching Hospitals NHS Trust

      Podcast Guest Speakers

      Dr Jenny Hughes

      The Princess of Wales Hospital, Wales


      Dr Hamish Hunter

      The University of Manchester



      JULY: Episode 1

      Clinical trial spotlight - risankizumab and secukinumab head-to-head in plaque psoriasis

      AUGUST: Episode 2

      Psoriasis in the time of COVID-19: an era of virtual clinics?             

      SEPTEMBER: Episode 3

      Psoriasis in practice: BAD guideline updates                               

      OCTOBER: Episode 4

      BAD 2020: virtual congress highlights

      NOVEMBER: Episode 5

      Are all IL-23s the same?                    

      DECEMBER: Episode 6

      EADV 2020: congress highlights       


      1. SKYRIZI (risankizumab) Summary of Product Characteristics.
      2. Smith CH, et al. BJD 2020, Published: March 18, 2020. DOI:10.1111/bjd.19039.
      3. BAD 2020 guideline update: NMA bjd19039-sup-0002-FileS2.docx (Accessed August 2020).

      UK-RISN-210516 Date of Preparation: October 2021